Navigation Links
CuraGen and TopoTarget Initiate Phase I/II Clinical Trial of Belinostat (PXD101) Combination Therapy for Acute Myeloid Leukemia
Date:8/28/2007

BRANFORD, Conn., Aug. 28 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN) and TopoTarget A/S (Copenhagen Stock Exchange: TOPO) announced today the initiation of patient dosing in a Phase I/II clinical trial evaluating belinostat (PXD101), a histone deacetylase (HDAC) inhibitor, in combination with the anthracycline idarubicin for the treatment of Acute Myeloid Leukemia (AML). The trial is being conducted at multiple sites in the European Union.

Patients under the age of 60 with relapsed or refractory AML, or patients over 60 with newly diagnosed or previously treated AML, are eligible for enrollment in the trial. Initially, 24 to 40 patients will be enrolled into one of two treatment arms and receive intravenous treatment with a combination of belinostat and idarubicin. Patients will receive standard doses of idarubicin in combination with either belinostat administered intravenously once daily for five days, or a continuous infusion of belinostat over 24 to 48 hours. Enrollment into the arms will occur in parallel in order to assess safety and define the maximum tolerated dose (MTD) for each treatment regimen. Upon establishing the MTD for each treatment arm, the trial will be advanced into Phase II to further define the safety and efficacy of belinostat in combination with standard doses of idarubicin.

Patients demonstrating complete or partial response, as defined by the Revised Recommendations of the International Working Group, will continue to receive treatment with belinostat until disease progression. The primary objectives for the study include safety, tolerability, and efficacy for each treatment regimen. Secondary objectives include time to response, duration of response, and surviva
'/>"/>

SOURCE CuraGen Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. CuraGen Presents Update on Clinical Development Program for Belinostat
2. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
3. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
4. Malvern initiates European user group meetings for chemical imaging
5. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
6. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
7. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , Sept. 18, 2014  ADM Tronics ... DeNovi , Ph.D. to its corporate Advisory Board ... an instructor at the Harvard Medical School and ... Rome.  He received his Masters degree in Electronics ... Systems from the University of Bologna. After spending a ...
(Date:9/18/2014)... MiMedx Group, Inc. (NASDAQ: ... of patent protected regenerative biomaterials and bioimplants processed ... has entered into a distribution agreement with Zimmer, ... dehydrated human amnion/chorion membrane ("dHACM") allograft products to ... private label basis. The MiMedx dHACM ...
(Date:9/18/2014)... PLAINSBORO, N.J. , Sept. 18, 2014 ... the National Hemophilia Foundation,s (NHF) new three-year initiative, ... to people with hemophilia and their families/caregivers to ... can impede disease management. The curriculum for the ... Your Provider About Pain , focuses on improving ...
Breaking Medicine Technology:ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 2ADM Tronics Appoints Gianluca DeNovi, Ph.D. To Advisory Board 3MiMedx Signs Distribution Agreement With Zimmer 2MiMedx Signs Distribution Agreement With Zimmer 3Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 2Novo Nordisk Supports National Hemophilia Foundation Initiative for "Collaborating in Care" Disease Management Program 3
(Date:9/18/2014)... "Medical staff need better ways to ... the patient's privacy," said one of two inventors from ... order to supply caregivers with the equipment they need ... prototype for The Helper to make it easier to ... patient onto his or her side. It also securely ...
(Date:9/18/2014)... One of the most capable and sophisticated ... ShandsCair Flight Program’s new EC155 B1, will be ... the Air Medical Transport Conference (AMTC), Sept. 22-24, in ... service ShandsCair EC155 and the Vanderbilt University LifeFlight ... highlight Airbus Helicopters broad, industry leading line-up of ...
(Date:9/18/2014)... Alan Mozes HealthDay ... When it comes to emergency room waiting times, patients seeking ... time staring down the clock than those seen at smaller ... of crowding and our ability to provide timely emergency care ... of the authors of the new research, Dr. Renee Hsia, ...
(Date:9/18/2014)... true: exercise is good for you. But new research ... have an added benefit for cancer patients undergoing chemotherapy. ... melanoma, found that combining exercise with chemotherapy shrunk tumors ... associate professor in the School of Nursing and director ... was the senior author on the study, which appears ...
(Date:9/18/2014)... 18, 2014 TayganPoint Consulting Group, ... that President and co-founder John Cassimatis was named ... Winners for 2014, recognizing the region’s top healthcare ... emerging executive of the year. , The Innovation ... sciences that continue to shape the medical industry ...
Breaking Medicine News(10 mins):Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 3Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 4Health News:ER Waiting Times Vary Significantly, Studies Find 2Health News:ER Waiting Times Vary Significantly, Studies Find 3Health News:Exercise boosts tumor-fighting ability of chemotherapy, Penn team finds 2Health News:TayganPoint Executive Receives Prestigious Award from Philadelphia Business Journal 2
... 280 cases of malaria due to Plasmodium falciparum on the ... these reported cases, 264 have occurred in Kingston// , 12 ... Clarendon. There have been no reported deaths due to malaria. ... from the WHO Regional Office for the Americas coordinated by ...
... researchers based in the UK has found a way to ... potential for a new form of drug delivery// . ... of London, chemically modified carbon nanotubes by adding a range ... to enter a variety of cell types, including human cancer ...
... in the military have higher blood pressure, heart rates and ... . ,Researchers looked at 121 adolescents – including ... Iraq and 53 with a parent in the military but ... launched in March 2003 and nearly three months later when ...
... an independent risk factor for HIV infection, according to ... Sexually Transmitted Infections. The researchers conducted// a meta-analysis of ... looking at the link between smoking and progression to ... ,There is a growing recognition that smoking can increase ...
... Indian Affairs Committee on Thursday approved by voice ... to provide mental health services for suicide// prevention, ... Alaska Natives through expanded telemedicine systems, CongressDaily reports. ... committee Chair Byron Dorgan (D-N.D.), five tribes or ...
... used to treat diabetes and thought to hold great ... syndrome (PCOS), is less useful for helping women with ... with the infertility drug clomiphene, report researchers in an ... largest, most comprehensive effort yet to compare the two ...
Cached Medicine News:Health News:Carbon Nanoneedles For Drug Delivery 2Health News:Carbon Nanoneedles For Drug Delivery 3Health News:Carbon Nanoneedles For Drug Delivery 4Health News:Wartime Raises Stress, BP Rates in Military Offspring 2Health News:Smoking Increases Risk of HIV Acquisition 2Health News:Standard Therapy More Effective in Common Fertility Disorder 2Health News:Standard Therapy More Effective in Common Fertility Disorder 3
The Guidant Fineline II Sterox Atrial J is a steroid-eluting pacing lead designed for permanent implantation for either atrial or ventricular applications....
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: